Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

MetaVia Inc. ( Nasdaq: MTVA) announced that a late-breaking abstract highlighting Phase 2a data from its DA-1241 program in presumed metabolic dysfunction-associated steatohepatitis (MASH) has been ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical ...

Structure Therapeutics Inc.’s GPCR share price has surged by 29.14%, which has investors questioning if this is right time to sell.

and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus ...

DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well ...

MetaVia (MTVA) announced positive results from the 4-week multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, ...

From Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville Campus, Victoria, Australia (R.H.R.) Division of Endocrinology and Metabolism (E.D.A.), ...

Most of us don't check our kids' blood sugar. So, chances are you don't know if it's healthy. Still, there may be clues that your child's levels are out of whack, and you may want to give your ...

Compounded semaglutide and Ozempic should contain the same active ingredient: semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist. A key difference between compounded ...

Drucker and three co-winners made discoveries about glucagon-like peptide-1 in their labs. The other recipient of the award, Lotte Bjerre Knudsen, who works for Novo Nordisk, led the way in ...